What jumps out to me is not “structural decline,” but a business whose accounting earnings have become a poor shorthand for underlying operating health. Revenue moved from $22.75B in 2023 to $23.16B in 2024 and then $25.20B in 2025, so this is still a company adding real top-line dollars at scale, not one stalling out. More important, operating income did not deteriorate with the 2025 GAAP loss; it improved sharply to $1.23B from $813.5M in 2024 and above $1.05B in 2023. Gross profit also rose to $6.44B from $5.83B. That tells me the core engine — ticketing, sponsorship, and promotion economics in aggregate — is still expanding. The problem is capital intensity and below-the-line leakage: $1.40B of operating cash flow only turned into $333.6M of free cash flow because capex hit $1.06B, while the balance sheet remains thin with just $271M of book equity against $10.40B of debt. So my read is simpler than the headline loss suggests: this is an economically solid franchise carrying a valuation that assumes that operating gains will convert to equity value much more cleanly than they currently do.

The quarterly pattern also matters, but I read it differently from a “2023 was the peak” narrative. Yes, Q3 2024 was weaker than Q3 2023, with revenue down from $8.15B to $7.65B and net income down from $521.5M to $451.8M, and Q1 2025 revenue fell to $3.38B from $3.80B. But the intervening quarters were not broken: Q2 2024 revenue rose to $6.02B from $5.63B in Q2 2023, and Q4 2024 profit was positive $201.0M versus a loss of $248.7M in Q4 2023. That does not look like a business rolling over; it looks like a highly seasonal one with lumpy touring calendars and uneven comparables. The more durable concern is not demand collapse but margin ceiling. Annual operating margin was only 4.9% in 2025, despite record revenue, and free cash generation on $25.2B of sales was just 1.3%. At $41.25B market cap and 22.6x EV/EBITDA, the stock is priced as though these operating gains will mature into far better shareholder cash returns than the recent record shows.

On Opus specifically: I agree with the core valuation conclusion and with the statement that the 2025 GAAP loss should not be waved away. I also agree with Opus that 22.6x EV/EBITDA is too rich for a business carrying an active DOJ overhang and cyclical exposure. Where I disagree is the claim that “the top of the cycle looks like it printed in 2023” and that 2025 revenue growth is being carried by “mix/pricing, not attendance.” The data provided do not support that level of certainty. We have quarterly revenue and net income, not attendance, ticket volume, or segment mix. A down Q3 and down Q1 are real, but they coexist with full-year revenue growth to $25.20B and stronger operating profit. That is not evidence of a peak having definitively passed; it is evidence that post-reopening comps have gotten tougher and profitability has become more dependent on non-GAAP line items and capital allocation discipline. I also think Opus overstates debt distress. Net debt is roughly $3.3B after $7.09B of cash, which is meaningful but not existential relative to $1.23B of operating income and $1.40B of operating cash flow. The issue is not solvency; it is that equity holders are paying a premium multiple for a balance sheet and cash-flow profile that deserve a discount.

I agree with Opus’s observation that the market is effectively capitalizing Ticketmaster-like quality while underpricing the regulatory asymmetry. I also agree that the tiny insider sales and awards are close to meaningless. But I disagree with the framing that the setup is dramatically asymmetric to the downside unless one assumes a breakup. Without a severe regulatory remedy, this is still a scaled, cash-generating live-entertainment platform with rising gross profit and operating income, and that matters. My issue is narrower and more concrete: at $179, investors are paying for an outcome where the company sustains mid-to-high single-digit revenue growth, protects margins, and improves FCF conversion from $333.6M to something far closer to $1B. That is possible, but the current evidence does not justify paying up for it. A more sensible range is around 18-20x EBITDA for a business with modest growth, heavy seasonality, regulatory noise, and weak equity cushion, which gets me to an equity value closer to the mid-$150s than to $179.

A careful skeptic of both my view and Opus’s would say we are both overfitting messy post-COVID comparisons and underestimating how much accounting distortions, working capital swings, and venue investment can obscure normalized earnings power here. They would also say a company that can grow gross profit from $5.46B in 2023 to $6.44B in 2025 may deserve a premium even before free cash flow catches up, especially if 2026 touring calendars rebound. That is fair. But until the company proves that rising operating profit can consistently translate into materially better free cash flow and until the DOJ cloud is better bounded, I would not pay nearly $42B of equity value for that promise.